开源证券股份有限公司 关于江苏德源药业股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 单位: 万元 | | | | 募集资金计 | 累计投入 | | | --- | --- | --- | --- | --- | --- | | | 募集资金用 | | 划投资总额 | 募集资金 | 投入进度(%) | | 序号 | 途 | 实施主体 | (调整后) | 金额 | (3)=(2)/(1) | | | | | (1) | (2) | | | | 原料药和制剂 生产综合基地 | 公司 | 18.000.00 | 2.267.19 | 12.60% | | | 项目一期工程 | | | | | | 2 | 研发中心建设 | 公司 | 5.000.00 | 704.60 | 14.09% | | | 项目 | | | | | 开源证券股份有限公司(以下简称"开源证券"或"保荐机构")作为江苏德源 药业股份有限公司(以下简称"德源药业"或"公司")向不特定合格投资者公开发 行股票的保荐机构,根据《证券发行上市保荐业务管理办法》《北京证券交易所 证券发行上市保荐业务管理细则》《北京证券交易所股票上市规则（试行)》 ...

证券代码：832735 证券简称：德源药业 公告编号：2023-004 江苏德源药业股份有限公司 董事会 2023 年 3 月 30 日 1 / 1 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏德源药业股份有限公司《2022 年年度报告》及《2022 年年度报告摘要》 于 2023 年 3 月 30 日在北京证券交易所官方信息披露平台（www.bse.cn）披露， 敬请投资者注意查阅。 特此公告。 江苏德源药业股份有限公司 2022 年年度报告披露的提示性公告 ...

证券代码：832735 证券简称：德源药业 公告编号：2023-027 江苏德源药业股份有限公司 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 本次年度股东大会召开程序符合《中华人民共和国公司法》等相关法律法规 和《江苏德源药业股份有限公司章程》中有关召开年度股东大会的规定。因此， 本次股东大会的召开合法、合规。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 本次会议采用现场投票和网络投票相结合的方式召开，公司同一股东应选 择现场投票、网络投票或其他表决方式的一种方式，如果同一表决权出现重复 投票表决的，以第一次投票表决结果为准。 关于召开 2022 年年度股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 本次会议为 2022 年年度股东大会。 （二）召集人 （五）会议召开日期和时间 1 / 7 1、现场会议召开时间：2023 年 4 月 20 日 13:30。 2、网络投票起止时间：202 ...

证券代码：832735 证券简称：德源药业 公告编号：2023-025 江苏德源药业股份有限公司征集投票权实施细则 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 江苏德源药业股份有限公司于 2023 年 3 月 29 日召开第三届董事会第十七次 会议，会议审议通过《关于制定<董事、监事和高级管理人员所持本公司股份及 其变动管理制度>等三部管理制度的议案》。表决结果：同意 9 票；反对 0 票；弃 权 0 票。本议案尚需提交股东大会审议。 1 / 7 二、 制度的主要内容，分章节列示： 第一章 总 则 第一条 为切实保护股东利益，促使广大股东积极参与公司管理，完善公司 法人治理结构，规范征集投票权行为，根据《中华人民共和国公司法》《中华人 民共和国证券法》《公开征集上市公司股东权利管理暂行规定》《北京证券交易所 股票上市规则（试行）》等法律法规、规范性文件和《江苏德源药业股份有限公 司章程》（以下简称"公司章程"）的有关规定，制订本细则。 第二条 本细则所称征集投票权，是指公司召开 ...

证券代码：832735 证券简称：德源药业 公告编号：2023-026 江苏德源药业股份有限公司董事、监事和高级管理人员薪 酬管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 江苏德源药业股份有限公司于 2023 年 3 月 29 日召开第三届董事会第十七次 会议，会议审议通过《关于制定<董事、监事和高级管理人员所持本公司股份及 其变动管理制度>等三部管理制度的议案》。表决结果：同意 9 票；反对 0 票；弃 权 0 票。本议案尚需提交股东大会审议。 二、 制度的主要内容，分章节列示： 第一章 总则 第一条 为进一步加强和规范江苏德源药业股份有限公司（以下简称"公司"） 董事、监事和高级管理人员（以下简称"董监高人员"）薪酬的管理，科学、客观、 公正、规范地评价公司董监高人员的经营业绩，建立和完善有效的激励与约束机 制，充分调动董监高人员的工作积极性和创造性，提高公司的经营管理效率，促 进公司的持续健康发展,根据《中华人民共和国公司法》及其他有关法律、法规、 规范性文件和《 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据公司治理专项自查及规范活动的相关要求，江苏德源药业股份有限公司 （以下简称"公司"或"上市公司"）结合《中华人民共和国公司法》《中华人民共 和国证券法》《北京证券交易所股票上市规则（试行）》等法律法规及《江苏德源 药业股份有限公司章程》等内部规章制度，按照公司治理有关文件的精神，严格 对公司治理情况进行了自查。现将自查情况、自我规范情况报告如下： 一、 公司基本情况 公司属性为民营企业。 公司存在实际控制人，公司的实际控制人为李永安、徐维钰、陈学民、任路、 徐根华、范世忠、郑家通、张作连、徐金官、何建忠、孙玉声，截至 2022 年 12 月 31 日，上述 11 名自然人股东直接持有公司 54.11%的股份，李永安、徐根华、 何建忠、张作连、徐金官及孙玉声通过其控制的连云港威尔科技发展有限公司间 接持有公司 1.04%的股份。综上，实际控制人能够实际支配的公司有表决权股份 总数占公司有表决权股份总数的比例为 55.15%。 证券代码：832735 证券 ...

Financial Performance - The company achieved operating revenue of CNY 635,047,016.37, representing a year-on-year increase of 23.59%[3] - Net profit attributable to shareholders reached CNY 120,200,356.40, up 54.32% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 103,053,921.12, reflecting a growth of 50.39%[3] - Basic earnings per share increased to CNY 1.91, a rise of 45.80% year-on-year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 999,216,907.56, an increase of 19.24% from the beginning of the period[3] - Shareholders' equity attributable to the company was CNY 817,416,485.37, up 18.22% from the start of the period[3] Sales and Market Development - The company focused on enhancing sales and market development, leading to steady growth in product sales[6] - The sales of key compound products "复瑞彤" and "波开清" saw significant increases, contributing to improved product structure and higher overall gross margin[6] Cost Management - The company optimized internal management and reduced costs, resulting in lower sales and management expense ratios compared to the previous year[7] Reporting Status - This earnings report is preliminary and has not been audited, with final figures to be confirmed in the annual report[8]

Financial Performance - The estimated net profit attributable to shareholders for 2022 is projected to be between 11,000 and 12,500 thousand yuan, representing an increase of 41.22% to 60.48% compared to the previous year's net profit of 7,789.07 thousand yuan [3]. - The growth in net profit is primarily driven by the steady increase in sales volume of existing products and the launch of new products such as Ipatasertib tablets and Acarbose tablets, which have contributed to sustainable growth in operating performance [5]. - Significant sales growth was observed in the promoted compound products "Furuitong" and "Bokaiqing," leading to an increase in the number of patients served and an optimization of the product structure, enhancing the overall gross profit margin [5]. Management and Operations - The company has strengthened internal management, optimized personnel structure, and strictly controlled expenses, resulting in improved profitability [5]. - The financial data presented is preliminary and has not been audited, and the final figures will be disclosed in the official 2022 annual report [6].

证券代码：832735 证券简称：德源药业 公告编号：2023-001 江苏德源药业股份有限公司 关于卡格列净片（0.1g）获国家药监局 江苏德源药业股份有限公司（以下简称"公司"）于 2023 年 1 月 11 日取得国 家药品监督管理局签发的按照化学药品 4 类申报的卡格列净片（规格：0.1g）的 药品注册证书，且视同通过一致性评价。现将相关信息公告如下： 一、药品基本情况 规格：0.1g 注册分类：化学药品 4 类 批准文号：国药准字 H20233014 签发药品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 二、对公司的影响及风险提示 本次获得卡格列净片的药品注册证书，进一步丰富了公司在糖尿病领域的产 品管线，并与现有糖尿病领域产品形成协同效应、巩固并提升公司在糖尿病领域 的品牌效应和市场竞争力。 药品获得注册证书后，该产品由于受到市场环境和国家政策等因素的影响， 生产和销售情况会存在一定不确定性。敬请广大投资者谨慎决策，注意防范投资 风险。 从而降低血糖。该类靶点药物与其他降糖 ...

Financial Performance - Operating revenue for the first nine months of 2022 was ¥470,360,144.98, representing a growth of 24.74% from ¥377,071,819.12 in the same period of 2021[16] - Net profit attributable to shareholders for the first nine months of 2022 was ¥70,171,109.16, up 26.68% from ¥55,393,002.13 year-on-year[16] - The gross profit margin for the same period was 79.85%, an increase of 2.03 percentage points year-on-year[23] - Total revenue for Q3 2022 reached ¥160,480,076.60, a 24.5% increase compared to ¥128,953,278.59 in Q3 2021[108] - Operating profit for Q3 2022 was ¥23,792,641.80, compared to ¥17,349,376.68 in Q3 2021, indicating a growth of 37.1%[109] - The company's net profit for Q3 2022 was approximately ¥19.43 million, a 33.5% increase from ¥14.62 million in Q3 2021[110] - The company reported a total profit of ¥19.05 million for Q3 2022, up from ¥15.96 million in Q3 2021, indicating a growth of 13.1%[114] Cash Flow - The net cash flow from operating activities for the first nine months of 2022 was ¥107,662,146.09, reflecting a 37.28% increase compared to ¥78,424,504.28 in the previous year[16] - Total cash inflow from operating activities reached CNY 475,179,838.70, up from CNY 373,096,524.00, reflecting a growth of 27.4% year-over-year[116] - Cash outflow for operating activities was CNY 367,517,692.61, compared to CNY 294,672,019.72 in 2021, representing an increase of 24.7%[116] - Financing activities resulted in a net cash outflow of CNY 21,879,398.28, a significant decrease from a net inflow of CNY 297,341,775.02 in 2021[118] Assets and Liabilities - Total assets as of September 30, 2022, reached ¥941,467,534.42, an increase of 12.34% compared to ¥838,022,957.26 at the end of 2021[15] - Total liabilities increased to ¥175,843,084.10 from ¥146,568,023.42, marking a rise of around 19.9%[102] - The equity attributable to shareholders rose to ¥765,624,450.32, up from ¥691,454,933.84, which is an increase of about 10.7%[102] - The company's accounts receivable at the end of the reporting period amounted to ¥110,485,900, a 16.39% increase, with a receivables turnover rate of 4.34, up from 4.06 in the previous year[18] Investments and R&D - Research and development expenses for the period were 50.81 million yuan, a year-on-year increase of 29.50%[24] - The company's long-term equity investments reached ¥9,703,100, primarily due to a capital increase of ¥10,000,000 to Beijing Jingda Biotechnology Co., Ltd.[19] - The company approved an investment of ¥8,000,000 in financial products and ¥80,000,000 in bank principal-protected products to enhance fund utilization efficiency[41] Shareholder Information - The largest shareholder, Li Yong'an, holds 6,761,216 shares, accounting for 10.36% of total shares[32] - The second-largest shareholder, the State-owned Research Institute, holds 6,300,000 shares, representing 9.66% of total shares[32] - The total number of unrestricted shares increased from 43,878,944 to 44,895,944, representing a rise from 67.25% to 68.81% of total shares[32] Commitments and Compliance - The company has ongoing commitments regarding environmental assessment procedures for certain products that did not obtain the necessary approvals between 2013 and 2014[51] - The company has committed to stabilizing its stock price as outlined in the stock issuance prospectus, with commitments valid until February 2024[51] - The company will publicly explain any failure to implement the promised measures to stabilize share prices and apologize to shareholders and the public investors[63] Market Outlook and Strategy - The company emphasizes strengthening R&D investment and market expansion to enhance its competitive and sustainable profitability, focusing on endocrine therapy drug development and sales[64] - The company aims to improve management efficiency and profitability by optimizing production processes and enhancing information management across procurement, production, inventory, and sales[65] - The company plans to review its shareholder dividend return plan at least every three years after listing on the selected tier, considering the opinions of shareholders and independent directors[71]